Sociodemographic and clinical characteristics of the study sample (N=50)
| Age, years, median (IQR) | 46 (39–51) |
| Women n, (%) | 41 (82) |
| Healthcare worker, n, (%) | 21 (42) |
| Comorbidities, n, (%) | 39 (78) |
| Hypertension | 5 (10) |
| Diabetes | 1 (2) |
| Hypothyroidism | 8 (16) |
| Anxiety or depressive disorders | 5 (10) |
| Endometriosis | 4 (8) |
| Migraine | 4 (8) |
| Current cigarette smoking, n, (%) | 7 (14) |
| Alcohol consumption >3 times/week, n, (%) | 3 (6) |
| Educational level, n, (%) | |
| Below end of high school | 1 (2) |
| End of high school | 10 (20) |
| Tertiary education | 39 (78) |
| Having children, n, (%) | 35 (70) |
| Date range of first COVID-19 symptoms, n, (%) | |
| From mid-February 2020 to end of April 2020 | 40 (80) |
| From May 2020 to November 2020 | 10 (20) |
| Family or friends affected by severe COVID-19 | 13 (26) |
| No of symptoms per patient during acute COVID-19, median (IQR) | 6 (5–8) |
| Type of symptoms during acute COVID-19, n, (%) | |
| Asthenia | 39 (78) |
| Fever | 35 (70) |
| Cough | 34 (68) |
| Headaches | 32 (64) |
| Diffuse pain | 30 (60) |
| Anosmia | 29 (58) |
| Dyspnoea | 25 (50) |
| ENT symptoms | 24 (48) |
| Digestive symptoms | 18 (36) |
| Chest pain | 14 (28) |
| Palpitations | 8 (16) |
| Dizziness | 7 (14) |
| Dysesthesia | 1 (2) |
| Microbiological documentation*, n, (%) | 32 (64) |
| Time from first COVID-19 symptoms to phone interview, days, median (IQR) | 425 (403–429) |
| No of symptoms per patient at phone interview, median (IQR) | 13 (12–16) |
| Fluctuation of post-COVID-19 symptoms, n (%) | 44 (88) |
| Presence of worsening factors, n (%) | 37 (74) |
| Stress or negative emotions, n (%) | 23 (46) |
| Physical effort, n, (%) | 26 (52) |
| Both, n (%) | 13 (26) |
| Presence of soothing factors, n (%) | 41 (82) |
| Rest, n (%) | 20 (40) |
| Other (medication, physical activities, complementary medicine) | 32 (64) |
| None | 9 (18) |
| General trend of improvement, n (%) | 36 (72) |
*Positive RT-PCR on nasopharyngeal swab and/or positive COVID-19 serology.
ENT, ears, nose and throat.